PDCD1 and gastroesophageal junction adenocarcinoma: The PD-1 inhibitor pembrolizumab, which can be used to treat patients with recurrent, locally progressed, or metastatic gastric or gastroesophageal junction adenocarcinoma, was approved by the US Food and Drug Administration (FDA) in 2017 [2].